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Advanced glycation end products (AGEs) have been implicated in multiple organ failure,
predominantly via their cellular receptor (RAGE) in preclinical studies. Little is known about
the time course and prognostic relevance of AGEs in critically ill human patients, including
those with severe sepsis.
Objective
1) To explore the reliability of Skin Autofluorescence (AF) as an index of tissue AGEs in ICU
patients, 2) to compare its levels to healthy controls, 3) to describe the time course of AGEs
and influencing factors during ICU admission, and 4) to explore their association with dis-
ease severity, outcome, and markers of oxidative stress and inflammation.
Methods
Skin AF, serum N"-(carboxyethyl)lysine (CEL), N"-(carboxymethyl)lysine (CML), and solu-
ble RAGE (sRAGE) were serially measured for a maximum of 7 days in critically ill ICU
patients with multiple organ failure and compared to age-matched healthy controls.
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Correlations with (changes in) clinical parameters of disease severity, LDL dienes, and
CRP were studied and survival analysis for in-hospital mortality was performed.
Results
Forty-five ICU patients (age: 59±15 years; 60%male), and 37 healthy controls (59±14;
68%) were included. Skin AF measurements in ICU patients were reproducible (CV right-
left arm: 13%, day-to-day: 10%), with confounding effects of skin reflectance and plasma bil-
irubin levels. Skin AF was higher in ICU patients vs healthy controls (2.7±0.7 vs 1.8±0.3 au;
p<0.001). Serum CEL (23±10 vs, 16±3 nmol/gr protein; p<0.001), LDL dienes (19 (15–23)
vs. 9 (8–11) μmol/mmol cholesterol; <0.001), and sRAGE (1547 (998–2496) vs. 1042 (824–
1388) pg/ml; p = 0.003) were significantly higher in ICU patients compared to healthy con-
trols, while CML was not different (27 (20–39) vs 29 (25–33) nmol/gr protein). While CRP
and LDL dienes decreased significantly, Skin AF and serum AGEs and sRAGE did not
change significantly during the first 7 days of ICU admission. CML and CEL were strongly
correlated with SOFA scores and CML above the median at baseline was associated with
increased risk for mortality (Hazard ratio 3.3 (1.3–8.3); p = 0.01). All other markers did not
correlate with disease severity and did not predict mortality.
Conclusions
This study demonstrates that markers for the AGE-RAGE axis are elevated in critically ill
patients compared to healthy controls but remain stable for at least 7 days despite clearly
fading inflammation and oxidative stress. Circulating AGEs may be associated with disease
severity and outcome. Further research should be conducted to elucidate the role of the
AGE-RAGE axis in the exaggerated inflammatory response leading to multiple organ failure
and death, and whether or not this may be a target for treatment.
Introduction
Multiple organ failure is often caused by the systemic inflammatory response syndrome and is
associated with high mortality [1,2]. Although the systemic inflammatory response syndrome
is a physiologic host response to infection and injury, it is also accompanied by the production
of reactive oxygen species and insufficiency of the detoxifying system, leading to oxidative
stress [3]. Oxidative stress has been shown to promote the development of multiple organ fail-
ure [4] and is associated with an unfavourable outcome in patients with sepsis [5].
Unfortunately, assessment of oxidative stress in clinical studies is difficult because of the highly
unstable nature of reactive oxygen species [6]. Advanced glycation end products (AGEs) are stable
products, originally only considered as products of the slowly occurring non-enzymatic glycation
(Maillard reaction) in chronic diseases such as diabetes. However, AGEs are also rapidly formed
during oxidative stress, which implicates a potential role in sepsis [7–12]. In preclinical studies,
AGEs have been shown to exaggerate the inflammatory response. They engage the multiligand
receptor for AGEs (RAGE) [13] to boost septicaemia [14]. RAGE-deficient mice are strongly pro-
tected against mortality due to polymicrobial sepsis [15]. Indeed, in human sepsis studies, skin
autofluorescence (Skin AF), a validated non-invasive tissue marker for cross linking AGEs [16],
and antibodies against non-N"-(carboxymethyl)lysine (CML) AGEs [17] were significantly ele-
vated. However, these markers for AGEs are not exclusively derived from oxidative stress.
The AGE-RAGE Axis in Critical Illness
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We performed an explorative pilot study in which we hypothesized that in critically ill
patients both tissue (Skin AF) and circulating AGEs (CML and N"-(carboxyethyl)lysine (CEL))
are elevated in concordance with the soluble receptor for AGEs and markers of lipid peroxida-
tive stress (LDL dienes) and inflammation (CRP) and that particularly circulating AGEs are
associated with disease severity and outcome. For this purpose, these markers were serially
measured in a well-defined prospective cohort of critically ill patients admitted to our ICU and
compared to healthy controls.
Methods
Subjects
Critically ill patients. Consecutive patients admitted to a 12 bed mixed medical/surgical
intensive care unit of the University Medical Center Groningen were screened for eligibility.
To guarantee critical illness, the inclusion criterion was an Apache II score of more than 18
points in a 24 h-period immediately before inclusion at an arbitrary moment during ICU
admission. Exclusion criteria were age less than 18 years and a history of diabetes or renal dis-
ease (serum creatinine>150 μmol/l before current admission), the latter being conditions clas-
sically associated with chronically increased AGE accumulation. Skin AF was measured and
blood samples were collected daily from inclusion (day 1) to day 7. Clinical data were prospec-
tively obtained. The study has been conducted according to the principles expressed in the
Declaration of Helsinki and was approved by the Institutional Review Board of the University
Medical Center Groningen, University of Groningen, The Netherlands (METc 2005/007).
Each participant or next of kin gave written informed consent. Medical treatment was accord-
ing to physicians’ discretion. As standard practice at our ICU, blood glucose levels were regu-
lated by short acting insulin infusion, aiming at glucose levels between 5.0 and 7.0 mmol/L
[18], and patients were fed via an enteral tube at a constant rate 24 hours a day.
Control subjects: healthy controls. A group of healthy controls was included for compari-
son. This was an age-matched historical control group of 37 volunteers, who were recruited by
advertisement and did not have more than one of the following cardiovascular risk factors:
hypertension, smoking, hypercholesterolemia or a family history of cardiovascular disease.
They also had normal femoral and carotid arteries on ultrasound examination. Exclusion crite-
ria were age less than 18 years and a history of diabetes or renal disease.
Objectives and outcome
Skin AF was assessed in ICU patients and healthy controls at baseline, on 7 consecutive days.
Blood markers were assessed at baseline and on 7 consecutive days in ICU patients and only
once in healthy controls. Because of limitations in the availability of blood samples, CRP,
CML/CEL, LDL dienes and sRAGE were determined for 19, 25, 33 and 29 healthy controls,
respectively. Clinical and routine laboratory parameters were assessed at baseline in ICU
patients and healthy controls, and on 7 consecutive days in ICU patients. The primary analysis
variable was the difference in Skin AF between ICU patients and healthy controls. Serum CML,
CEL, LDL conjugated dienes, sRAGE at inclusion, the time course of Skin AF and circulating
markers during the first 7 days after inclusion, organ failure, and in-hospital mortality were
secondary analysis variables.
Organ failure
To quantify organ failure, the parameters of the Sequential Organ Failure Assessment (SOFA)
score were used: paO2/FiO2 ratio for respiratory function, thrombocytes for hematologic
The AGE-RAGE Axis in Critical Illness
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function, bilirubin level for liver function, inotropic dosage for circulatory function, and creati-
nine level at inclusion and the need for renal replacement therapy for renal function [19].
AGE accumulation in the skin
The AGE-Reader (DiagnOptics Technologies BV, the Netherlands) and the procedure which
was used to measure the Skin AF have been described before [20–22]. The AGE-Reader has
been validated against skin biopsy levels in earlier studies in healthy subjects and patients with
diabetes or renal disease of the following AGEs: pentosidine, CML and CEL, as well as with col-
lagen-linked-fluorescence, which has been classically used as a standard for AGE accumulation
in tissue [23–25]. Repeated measurements in controls and diabetic patients showed an intra-
individual Altman error percentage of 5.0% on a single day and 5.9% for seasonal changes [23].
Skin AF was measured on the ventral site of both lower arms separately at each time point;
the average of these two measurements was used. Measurements were performed at a skin site
without visible vessels, scars, bruises, or other abnormalities. Skin temperature was measured
at the site of Skin AF measurement using a sensor which was kept in place for 15 minutes,
which is long enough to obtain a stable value. The presence of pitting oedema or haematoma at
a distance of less than 15 centimetres from the measurement site and the presence of i.v. cathe-
ters in the ipsilateral arm was documented.
Previous studies in stable patients have shown that Skin AF can only be measured reliably if
the absorption of excitation and fluorescence light in the skin is limited, which is below a skin
reflectance of<12%.[20]. Skin reflectance<12% may occur in persons with dark skin, usually
Fitzpatrick class VI or sometimes V. Since the current study was an explorative study and it
was not clear whether this threshold holds true for ICU patients, we have chosen to analyse
data of all patients, irrespective of their skin reflectance. In healthy controls with a wide age-
range we have found previously that Skin AF is clearly and strongly related to skin elasticity
(measured with Cutometer1), but not to skin hydration (Corneometer1), colour and ery-
thema (both Mexameter) (data not published). Also, Skin AF does not appear to change
directly following haemodialysis and ultrafiltration [26]. These data make it plausible to mea-
sure Skin AF reliably in ICU patients who have dynamic hydration and skin perfusion states.
To assess the reproducibility, the Coefficient of Variation (CV) was assessed in ICU patients by
calculating the right to left arm CV and the day-to-day CV and local sources of error were
assessed (skin reflectance, local skin temperature, edema, hematoma, and the presence of intra-
venous catheters).
Serummarkers
Blood samples were taken at the time of inclusion and in the next 6 days during early morning
blood sampling rounds. The blood was allowed to clot at room temperature in dark for 30–60
minutes. The serum was separated by centrifugation (2000g for 10 min at room temperature)
and divided in polypropylene tubes. EDTA (1 mg/ml) was added to the samples for LDL dienes
determination to prevent auto-oxidation of fatty acids. The samples were frozen immediately
and stored at -80°C until analysis.
Serum levels of CML and CEL were measured in the protein fraction by stable-isotope dilu-
tion tandem mass spectrometry [27,28]. Briefly, serum proteins were reduced with 100 mM
sodium borohydride in 0.2 M sodium borate buffer at pH 9.2 for 2 h. The proteins were precip-
itated with 20% trichloroacetic acid and hydrolyzed with 6 M HCl overnight at 110°C. HCl was
evaporated at 70°C under nitrogen and residues were resolved in 0.5 mM tridecafluorohepta-
noic acid. Analysis was performed using a C18 reverse phase column with a linear gradient of
acetonitril. CML and CEL were measured using a positive ionization mode with respectively
The AGE-RAGE Axis in Critical Illness
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[2H2]-CML or [2H4]-CEL as internal standard. Intra- and inter-assay coefficients of variation
were 4.8 and 7.0% for CML, and 5.0 and 9.7% for CEL, respectively. Concentrations of protein-
bound CML and CEL were adjusted for total protein levels and expressed as nmol/gr protein.
Serum levels of sRAGE were measured using a commercially available ELISA (R&D sys-
tems, Minneapolis, MN, USA) according to the manufacturer’s protocol. The intra- and inter-
assay CV were<10%.
The oxidation of LDL in vivo was assessed as the concentration of conjugated dienes in pre-
cipitated LDL as previously described [29]. We used nitric acid washed screw-capped glass
tubes in all steps of analysis in order to avoid artefacts. Briefly, serum LDL was precipitated
with buffered heparin (LEO Pharma A/S (Ballerup, Denmark)). The precipitate was resus-
pended in 0.10 M phosphate buffered saline, pH 8.0. Cholesterol concentration (detection limit
0.20 mmol/L) was determined with an enzymatic colorimetric method by Konelab 20XT ana-
lyzer (Thermo Fisher Scientific, Vantaa, Finland) and the rest of the suspension was used for
measuring conjugated dienes. Lipids were extracted from the LDL with the mixture of chloro-
form:methanol (3:1), evaporated to dryness with a gentle stream of nitrogen, and reconstituted
in cyclohexane. The concentrations of conjugated dienes were measured spectrophotometri-
cally at 234 and 300 nm. Absorbance units (difference A234–A300) were converted to molar
units using the molar extinction coefficient 2.95 × 104 M−1 cm−1 for conjugated dienes. The
conjugated diene concentration was calculated per cholesterol concentration in LDL (μmol/
mmol cholesterol). Interassay variations were 12.7% (n = 140, serum pool at conjugated diene
level of 8.3 μmol/mmol cholesterol) and 11.9% (n = 66, serum pool at conjugated diene level of
8.6 μmol/mmol cholesterol) and the detection limit of conjugated dienes was 10 μmol/L.
Statistical analysis
Power analysis was based on a small pilot study [30]. It was calculated that 28 patients and 28
controls had to be included to detect a difference in Skin AF of 0.33 au (15%) based on a stan-
dard deviation of 0.44 at a significance level of 0.05 with a power of 80%. Taking into account a
dropout rate of 35%, we included 45 patients.
Values are expressed as mean + standard deviation, median (interquartile range), or as the geo-
metric mean + standard deviation where applicable. Analyses were performed using Statistical
Package for Social Science version 22 (International Business Machines Corp., New York, USA) or
Graphpad Prism version 5.0 (Graphpad Software Inc., San Diego, USA). Differences between
groups of quantitative variables were analysed by student’s t-test if they were normally distributed.
Where appropriate aWelch correction was applied. For non-normally distributed data, the Mann-
Whitney U test was used. Qualitative variables were analysed by Pearson’s chi-square test. To com-
pare multiple groups of measurements one-way analysis of variance or the Kruskal-Wallis test
were used. Correlations between numeric data were analyzed with the Spearman rank method.
Stepwise linear regression was used to correct for potential confounders that show a univariate
correlation with Skin AF at p<0.10 at baseline. Forward conditional logistic regression was used
to test whether the difference in Skin AF between patients and controls was independent of con-
founders that were available, i.e. a history of cardiovascular disease and hypertension. Age and
gender were not included in the analysis because groups were matched on these variables. To
analyse time dependent associations of repeated measurement during the first 7 days in ICU
patients, Generalized Estimating Equation (GEE) analysis was used and data are presented as
(geometric) mean with 95% confidence intervals. Only if GEE show time association with
p<0.10, additional comparisons at individual time points were assessed using the above men-
tioned statistics. Survival was estimated by the Kaplan-Meier method, and comparisons were
made with the log-rank test. A p-value of 0.05 or less was considered to be statistically significant.
The AGE-RAGE Axis in Critical Illness
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Results
Baseline characteristics
Table 1 presents the characteristics of patients and healthy controls. All patients and controls
were Caucasian. ICU patients were critically ill, as evidenced by a median Apache II score of 24
at inclusion and an in-hospital mortality rate of 51 percent (3 patients died at the ward, all oth-
ers at the ICU). The mean SOFA score at inclusion was 11 + 4. Renal replacement therapy,
vasopressor therapy, and artificial ventilation were required in 62%, 98% and 96% of cases,
respectively. Most patients had sepsis with pneumonia and peritonitis as most important
sources.
Table 1. Baseline and outcome variables of ICU patients and healthy controls.
controls ICU patients p-value
n = 37 45
age [years] 59±14 59±15 0.93
Men 25 (68%) 27 (60%) 0.48
cardiovascular disease 0 7 (16%) 0.011*
hypertension 3 (8%) 14 (32%) 0.009**
diagnosis pneumonia 12 (27%)
peritonitis 12 (27%)
cholangitis 4 (9%)
sepsis, other 7 (15%)
pancreatitis 3 (7%)
other 7 (15%)
Apache II score at inclusion 24 (21–29)
SOFA score at inclusion 11±4
CRP [mg/L] 1.3 (0.7–2.2)a 224 (128–320) <0.001***
glucose [mmol/L] 4.8 (4.6–5.2) 6.6 (5.6–7.4) <0.001***
creatinine [μmol/L] 88 (84–97) 189 (128–267) <0.001***
treatment
renal replacement therapy 28 (62%)
vasopressor 44 (98%)
ventilation 43 (96%)
days between hospital admission and inclusion 3 (1–14)
days between ICU admission and inclusion 2 (1–3)
days between inclusion and death or discharge 23 (6–43)
length of stay [days] hospital 37 (15–55)
icu 13 (6–31)
death in hospital 23 (51%)
skin AF [au] 1.8±0.3 2.7±0.7 <0.001***
serum CML [nmol/gr protein] 29 (25–33) a 27 (20–39) 0.64
serum CEL [nmol/gr protein] 16±3 a 23±10 <0.001***
serum LDL dienes [μmol/mmol cholesterol] 9 (8–11) a 19 (15–23) <0.001***
serum sRAGE [pg/ml] 1042 (824–1388) a 1547 (998–2496) 0.003**
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Compared to the healthy controls, partly due to exclusion criteria for controls, significantly
more ICU patients had a history of cardiovascular disease or hypertension and higher levels of
CRP, glucose, and creatinine at inclusion.
Reproducibility of Skin AF in ICU patients
No structural difference was observed between Skin AF measured at the left and right arm of
individual ICU patients. The right-left arm CV was 13% and the day-to-day CV was 10%. The
CVs of skin reflectance were 11.6% and 6.8% respectively
Influence of local factors on skin AF measurement
Single measurements of Skin AF of the right and left arm correlated moderately with skin
reflectance measured at the same site (r = 0.391, p = 0.012 and r = 0.297, p = 0.059 respec-
tively), whereas no relation was observed with local oedema of the arm, hematoma, and
whether intravenous catheters were present at the ipsilateral arm. Also, skin temperature did
not correlate with Skin AF.
Comparison of Skin AF between ICU patients and controls
Skin AF at inclusion, which was defined as the primary analysis variable, was significantly
higher in ICU patients compared to healthy controls (Fig 1). This difference remained signifi-
cant (p = 0.015) after correction for skin reflectance, glucose, creatinine, prior hypertension, or
prior cardiovascular disease (p = 0.91).
Association of skin AF with baseline characteristics and circulating
markers in ICU patients
Skin AF measured at baseline, correlated positively with age (r = 0.49; p = 0.001), negatively
with LDL dienes (r = -0.36; p = 0.017) and bilirubin levels (r = -0.39; p = 0.008; Table 2), and
was significantly higher in smokers (3.1 vs 2.5; p = 0.04). It was not dependent on gender
(p = 0.19), did not correlate with the time between hospital or ICU admission and inclusion
(r = -0.11; p = 0.46 and r = -0.17; p = 0.27) and tended to be higher in patients on renal replace-
ment therapy (2.8 vs 2.4; p = 0.06) and prior hypertension (2.9 vs 2.5; p = 0.09). Although
skin AF correlated negatively with CML (r = -0.33; p = 0.029), this difference was blunted after
correction for bilirubin levels. Skin AF did not correlate with baseline CEL, CRP or sRAGE
(Table 2). Stepwise, linear regression yielded that of these factors only age was independently
associated with Skin AF (R2 = 0.43; standardized beta 0.66; p = 0.001).
Correlations between serum AGEs, CRP, LDL dienes, sRAGE and
bilirubin (Table 2)
Positive correlations were found between CML and CEL (r = 0.71, p<0.001) and between CML
or CEL and bilirubin (r = 0.66, p<0.001 and r = 0.35, p = 0.025). CML and CEL correlated neg-
atively with CRP (r = -0.56, p<0.001 and -0.41, p<0.01).
Comparison and intercorrelation of serummarkers between ICU
patients and healthy controls
Serum levels of CEL, sRAGE, LDL dienes, and CRP were significantly higher in ICU patients
compared with healthy controls (Fig 1). The median CML did not differ between patients and
controls, but an increased variance was observed in patients. The distribution of Skin AF, CRP,
The AGE-RAGE Axis in Critical Illness
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Fig 1. Dot density plot of Skin AF, serumAGEs, sRAGE, LDL dienes and CRP at inclusion, comparing ICU patients with healthy controls.
doi:10.1371/journal.pone.0160893.g001
The AGE-RAGE Axis in Critical Illness
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CML, CEL, LDL dienes, and sRAGE were the same across the diagnosis categories listed in
Table 1 (Kruskal-Wallis Test, p = 0.52, 0.29, 0.08, 0.27, 0.77 and 0.19, respectively). The Apache
II score did not correlate with any of the markers, whereas the SOFA score correlated with
CML and CEL levels (r = 0.54 (p<0.001) and 0.46 (p = 0.002) respectively). SOFA score did
not correlate with Skin AF, sRAGE, LDL dienes and CRP. Analysing the SOFA components
revealed a strong correlation between CML and the hepatic score (based on bilirubin level)
only (Kruskal-Wallis test, p = 0.001).
Association of baseline Skin AF and serummarkers with disease
outcome
Patients who died had a significantly higher SOFA score and were more likely to have been
admitted for pneumonia. However, non-survivors did not differ from survivors in age, cardio-
vascular history, and APACHE II score, nor were there any significant differences in Skin
AF, CML, CEL, LDL dienes, and sRAGE. Fig 2 shows survival curves, in which patients with
values above the median were compared with those below the median of the variable under
Table 2. Correlations between Skin AF, serumAGEs, sRAGE, LDL dienes, CRP and bilirubin level in critically ill patients at inclusion.
Spearman's rho (p-value) CML CEL CRP LDL dienes sRAGE bilirubin
Skin AF -0.33 (0.029)* -0.13 (0.40) 0.07 (0.66) -0.36 (0.017)* 0.06 (0.69) -0.39 (<0.01)**
CML 0.71 (<0.001)*** -0.56 (<0.001)*** 0.12 (0.43) 0.22 (0.16) 0.66 (<0.001)***
CEL -0.41 (<0.01)** 0.08 (0.60) 0.22 (0.16) 0.35 (0.025)*
CRP -0.12 (0.46) -0.16 (0.32) -0.27 (0.08)






Fig 2. Kaplan-Meier survival curves of Skin AF, serumAGEs, sRAGE, LDL dienes, CRP and the SOFA score. For each variable, the patients were split
in two groups, namely those with values above the median and those having values below the median. The two groups were compared by using the log rank
test.
doi:10.1371/journal.pone.0160893.g002
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consideration. As expected, SOFA score was a positive predictor of hospital mortality. Addi-
tionally, CML above the median was positively associated with mortality (Hazard ratio 3.3
(1.3–8.3); p = 0.01). All the other markers determined in this study, i.e. Skin AF, CEL, CRP,
LDL dienes and sRAGE, did not predict mortality.
Repeated measurements in ICU patients
GEE repeated measurement analysis demonstrated small and non-significant time effect on
Skin AF (p = 0.09), with only a small decrease in Skin AF from baseline (2.59 (2.37–2.81)) to
day 6 (2.42 (2.18–2.66); p = 0.012) and day 7 (2.45 (2.19–2.72); p = 0.086) in those with an ICU
length of stay of at least 7 days (Fig 3). Other relevant parameters identified as changing over
time were SOFA score (decrease; p<0.001; Fig 3), CRP (decrease; p<0.001; Fig 3), creatinine
(decrease; p<0.001), body weight (increase; p<0.001), PaO2/FiO2 ratio (increase; p<0.001),
norepinephrine dose (decrease; p<0.001), whereas glucose (p = 0.99) did not change signifi-
cantly. Of these parameters, CRP (p = 0.014), creatinine (p = 0.026), and body weight
(p = 0.015) were significantly associated with Skin AF over time, whereas SOFA (p = 0.113),
PaO2/FiO2 ratio (p = 0.91), and norepinephrine dose (p = 0.77) were not. In multivariate anal-
ysis, only CRP and body weight were independently associated with Skin AF over time. The
change in Skin AF from baseline to day 7 did not differ between those who died in the hospital
after surviving the first week and those who survived until discharge from the hospital (change
in Skin AF: -0.16±0.25 vs -0.12±0.46; p = 0.70).
Repeated measurements of blood markers and their relation with Skin
AF and disease severity
In those ICU patients who participated in the study for at least 7 days, CML (p = 0.55), CEL
(p = 0.26), and sRAGE (p = 0.082) did not change significantly over time. LDL dienes showed a
significant decline starting at day 5 compared to baseline (p<0.001). In multivariate analysis,
the change in CEL (p = 0.46), sRAGE (p = 0.89), and LDL dienes (p = 0.41) did not correlate
with the change in Skin AF. CML was negatively associated with Skin AF (p = 0.028). Skin AF
as well as CML were both also strongly associated with bilirubin levels over time, with Skin AF
showing a negative association (p = 0.023) and CML a positive (p<0.001). The association of
Skin AF with CML was blunted after correction for the change in bilirubin levels.
Discussion
In the current pilot study we explored the role of the AGE-RAGE axis in patients admitted to
ICU for critical illness. We have demonstrated that Skin AF, as a marker of chronic AGE accu-
mulation, can be measured in patients admitted to the ICU with a reasonable reproducibility,
but that several method and patient related confounding factors should be taken into account,
limiting far-reaching conclusions. This study shows that Skin AF is elevated in critically ill
patients compared to age-matched healthy controls, for which the study was primary powered.
Skin AF measured at baseline was independently associated with age only and not with factors
indicating acute illness such as SOFA score or CRP or circulating levels of markers of AGEs
and oxidative stress. Skin AF showed only a small decreasing non-significant trend during the
first 7 days after inclusion and was not associated with in-hospital mortality. At baseline, circu-
lating AGEs (CEL), sRAGE, and LDL dienes were significantly higher in ICU patients com-
pared to healthy controls. Although CML was not elevated, both CEL and CML were clearly
associated with markers for disease severity, including the well validated SOFA score. Further-
more, although CRP and LDL dienes as markers for inflammation and oxidative stress clearly
decreased over time, all markers for AGEs appeared to remain stable and did not parallel these
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changing markers. Finally, CML was positively and prospectively associated with in-hospital
mortality, while the other markers of the AGE-RAGE axis were not.
Because of several potential confounding factors at the ICU, we performed additional repro-
ducibility tests, showing that the CV between the right and the left arm as well as the day-to-
day CV were acceptable but higher than commonly seen in stable patients in previous studies.
We previously found that, in healthy subjects, skin AF is not influenced by skin colour and
hydration. In the current ICU population, we identified a negative association with skin reflec-
tance, indicating that the more light is absorbed, the lower the skin AF. This effect was small
and inconsistent between both arms. Also, some effects of local skin temperature and haema-
toma were present, but these can be accounted for when performing the measurement. An
interesting observation was the strong negative association with plasma bilirubin levels. This
may have been caused by absorption of autofluorescence light in the skin as bilirubin is known
to strongly absorb light of a wave length of around 460 nm, which is in the spectrum of the
autofluorescence measured with our method. These factors may have blurred the results and
may have masked subtle associations in the population.
Our baseline data on skin AF are in line with a previous study by Greven and others, who
showed remarkably higher age-adjusted Skin AF levels in patients with sepsis compared with
controls but no relation with severity of disease [16]. It remains unclear whether or not Skin
AF has increased during and as a result of the current acute illness. It can be hypothesized that
Skin AF was already higher prior to the current illness and reflects a higher susceptibility for
critical illness as a derivative of biological aging and decreased general health. This is substanti-
ated by our observation that Skin AF did not change during admission, with a day-to-day CV
of only 10%. Since the level of Skin AF observed in the patients from our study is markedly
higher than we measured in patients with chronic diseases [31]), at least an additional effect of
the acute illness is suggested. This may be explained by the differences in dynamics between tis-
sue and circulating AGEs. Tissue AGEs may be rapidly formed, but their turnover is very slow
and dependent on the half-life of collagen and other long lived proteins. Although circulating
AGEs such as CML are rapidly formed or derived from exogenous sources (food, smoking, cer-
tain drugs), but are also cleared very rapidly by the kidneys or catabolised in concurrence with
circulating proteins [7–12], these levels did not change during the current study. This may be
explained by the presence of renal failure in most ICU patients. This may also explain the lack
of correlation between serum AGEs and skin AF, which was previously also observed in
chronic diseases such as diabetes and renal failure [32]. Moreover, it has been shown that
AGEs (especially methylglyoxal (MGO)) may suppress myeloid and T-cell immune function
and increase susceptibility to infections, referred to as “immune glycation damage” [33],
thereby preselecting patients with higher a priori Skin AF levels.
It has been hypothesized that AGEs are causally involved in the exaggerated inflammatory
response by engagement of the multiligand receptor for AGEs (RAGE) [13], as supported by
rodent studies [14]. The results from our study are mixed and cannot substantiate this hypoth-
esis. A recent study by Andrades et al. found an inverse association between blood CML/CEL
levels and severity of sepsis and renal function [34]. The authors suggest that AGEs participate
in early stages of renal dysfunction by increasing permeability resulting in proteinuria.
Fig 3. Time course of SOFA score, Skin AF, circulating AGEs (CML and CEL), sRAGE, LDL dienes and CRP
of ICU patients during 7 days starting at inclusion.Geometric mean with 95% confidence intervals. The symbols
indicate the p-value compared to day 1: ns = non-significant; *:p<0.05; **:p<0.01; ***: p<0.001.Patients who died
or were discharged before day 7 were excluded from this analysis. GEE repeated measurement analysis showed
that SOFA score (p<0.001), LDL dienes (p<0.001) and CRP (p<0.001) were time related, while Skin AF (p = 0.09),
CML (p = 0.55), CEL (p = 0.26) and sRAGE (p = 0.082) were not.
doi:10.1371/journal.pone.0160893.g003
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However, if renal failure is already present, a wide base of literature suggests that circulating
AGEs would be increased [35–37]. Also, loss of AGEs due to proteinuria could not be the
explanation for the lower levels, because they quantified AGE levels relative to grams of protein
in the same way as we did in the current study. Therefore, it remains unclear how to explain
these apparently conflicting data and this underlines the complex nature of the AGE/RAGE
axis.
Although an inverse association between bilirubin and AGE levels was previously found in
subjects with Gilbert syndrome [38], in line with the hypothesis that bilirubin may have antiox-
idative properties [39], we observed the opposite. A strong positive correlation between biliru-
bin levels and CML was documented, which persisted after exclusion of extreme outliers. This
suggests a role of the liver in the production or breakdown of CML [40] and that it is not biliru-
bin per se, but the degree of liver failure that determines the levels of AGEs.
With respect to sRAGE, our results are in accordance with other studies which show
increased levels of sRAGE in critically ill patients with sepsis and acute lung injury [41–43].
However, we were not able to confirm the positive correlations of sRAGE level with mortality,
lung injury (paO2/FiO2 ratio), or renal replacement therapy that have been found by others
[41,44–46]. Brodska et al. studied a cohort of 54 critically ill septic patients and observed a sig-
nificant correlation between sRAGE and CRP on day 1, while they didn’t find a correlation
between these two parameters on day 3 [44]. This shows that correlations may change in the
course of the disease, possibly reflecting a changing role, for example from being a by-product
of apoptosis to getting a direct beneficial role by acting as a decoy receptor for RAGE ligands
such as AGEs, as has been suggested by others. Therefore the timing of measuring sRAGE in
the course of the disease may be essential for the interpretation of the results.
A remarkable finding in our study was the strong elevation of plasma CEL levels, whereas
the levels of CML were not increased. This may be explained by the fact that CEL and CML are
derived from different sources: CML is derived from glyoxal and CEL fromMGO. MGO can
be detoxified by glyoxalase 1 (GLO-1), which is an enzyme that has been shown to exhibit
reduced activity after stimulation with inflammatory mediators. Hence, resulting in increased
accumulation of MGO-derived AGEs such as CEL [28]. Unexpectedly, CRP correlated
inversely with serum levels of CML and CEL. This correlation was found with and without cor-
rection for total serum protein. In chronic settings, such as in patients with diabetes, some
authors found a positive correlation between CRP and blood AGEs [35,47], while others did
not [48,49]. An inverse correlation between CRP and CML in blood has also been found in
obesity [50], and it has been hypothesized that inflammation may result in trapping of CML in
tissue.
In the heterogeneous ICU population, the relation between CRP and AGEs formation may
be more complex, as CRP may predict multiple organ failure and poor outcome early in the
course of disease [51], while it may not be of prognostic significance in patients who already
have multiple organ failure [52], as in our study. It is difficult to speculate on the course of
AGEs during acute critical illness, because the relationship between CRP and AGEs may
change during the course of the disease and we did not document the course of AGEs prior to
developing multiple organ failure.
Although we found CML above the median to be associated with an increased mortality,
which is in line with our hypothesis of a detrimental role of oxidative stress and the AGE-R-
AGE axis in critical illness, we are reticent to draw far reaching conclusions. First, the other
AGE we studied, CEL, appeared not to be associated with increased mortality, nor did the LDL
dienes as markers of lipid peroxidative stress. This may suggest a random effect. Furthermore,
literature on this relation is conflicting. In hemodialysis patients, increased CML was associated
with mortality in one study [53], while it was found to be protective in another study [54].
The AGE-RAGE Axis in Critical Illness
PLOS ONE | DOI:10.1371/journal.pone.0160893 August 16, 2016 13 / 17
Andrades et al. also found that high levels of a combined ELISA assay for CML/CEL were asso-
ciated with a decreasing SOFA score and a better survival in patients with sepsis [34]. However,
this study included patients with a broader range of sepsis severity, with 20% of the patients
having sepsis without organ failure. This may be essential because patients were included
within 12 hours after sepsis diagnosis, while we included patients when they already had multi-
ple organ failure. This again underlines the importance of the timing of sampling during the
course of the disease.
Limitations
Major limitations of this study are the relatively small sample size and the heterogeneity of the
ICU population. Due to the small sample size, small interactions could have been overlooked.
Additionally, the magnitude of repeated assessment of biomarkers, could have introduced
coincidental findings. However, we have overcome this limitation be performing GEE analysis
for each biomarker. Our control group was too healthy to account for confounding factors
such as comorbidity and the contribution of the infection per se. Partly, we have overcome this
limitation by excluding patients with previous diabetes of renal failure. As AGEs and LDL
dienes are protein and lipid bound respectively, changes in protein and lipids during the cata-
bolic state of severe illness may have influenced the results. We have tried to bypass this by cor-
recting for total protein and cholesterol respectively. Also, infusion fluids used on the ICU may
contain amounts of glucose degradation products, which are precursors of AGEs, especially
MGO-derived AGEs such as CEL [55,56].
Conclusions
With the current study we underscore the complexity of AGE-RAGE axis in critical illness. To
the best of our knowledge, this is the first study to sequentially measure Skin AF and its poten-
tial confounders, circulating AGEs, and oxidative stress markers in critically ill patients.
Although CRP and the oxidative stress marker LDL-dienes do clearly decrease during the
course of ICU admission, circulating AGEs as well as Skin AF remain fairly stable, and hence
their role as a disease marker in ICU patients is questionable. Since all markers appeared to be
elevated in critically ill patients and circulating AGEs seemed to be associated with disease
severity and, potentially, outcome, the role of the AGE-RAGE axis deserves further study. To
unravel the course and relevance of AGE formation in critical illness, patients prone to develop
a systemic inflammatory response should be included early after, or even before the trigger.
The results from the current study will help in designing such future studies.
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